Downtown Los Angeles, California
GOOD SAMARITAN HOSPITAL
Los Angeles, CA
Officially Endorsed by:
THE HEART FAILURE SOCIETY OF AMERICA
INTERNATIONAL ACADEMY OF CARDIOLOGY
Update on Diagnosis and Therapy
April 21, 2018
2018 CME SURVEYS, SPEAKER SLIDE DOWNLOAD & SYLLABUS
For access to CME surveys and symposium materials, use your registration email address to login. Surveys are due by May 14, 2018.
IMPORTANT CME CREDIT NOTICE
CME Certificates will be issued digitally after Speaker and Symposium Surveys are completed.
Surveys are accessible after signing in with the email address you submitted during registration.
Surveys will be accessible online the day of the symposium and for 3 weeks following. You must complete the process by May 14, 2018 in order to receive your certificate. Certificates will be available online until January 1, 2019
and are printable directly from the website.
This Live activity, 22nd Annual Heart Failure 2018: An Update on Therapy , with a beginning date of 04/21/2018, has been reviewed and is acceptable for up to 6.5 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician's Recognition Award.
AANP: The American Academy of Nurse Practitioners accepts AAFP Prescribed credit. This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.
ANCC: According to the ANCC, the continuing education hours approved by the AAFP meet the ANCC-accredited CNE criteria.
AAPA: The American Academy of Physician Assistants accepts AAFP Prescribed credit for AAPA Category 1 CME credit.
This year's program provides a comprehensive update on the prevention, diagnosis and management of heart failure (HF). The program includes lectures presented by experts combined with interactive discussion with faculty. The extensive list of topics includes latest information on the management of hyperlipidemia, prevention of HF in patients with diabetes, extensive review of new drugs for the management of chronic HF and pulmonary hypertension, management of electrolyte abnormalities in HF, remote hemodynamic monitoring for prevention of hospitalizations, diagnosis and management of HF with reduced and preserved ejection fraction, HF in women and the approach to patients with new classification of mid-range ejection fraction. The program also includes discussion of new biomarkers, rate versus rhythm control and prevention of stroke in patients with HF and atrial fibrillation, amyloidosis, percutaneous mechanical circulatory support for high risk PCI, surgical revascularization and the value of myocardial viability assessment before surgery in patients with ischemic cardiomyopathy, transcatheter mitral valve repair for functional mitral regurgitation.
The 2018 program has been designed to provide a high level and clinically relevant update with a goal of improving the care of patients with heart failure.
At the conclusion of this activity, participants should be able to:
- Implement effective therapy for lipid disorders
- Manage diabetes in patients with heart failure
- Use new FDA approved drugs for the treatment of chronic heart failure
- Identify new therapeutic approaches for patients with chronic heart failure
- Manage patients with heart failure and preserved ejection fraction (HFpEF)
- Prevent and treat electrolyte abnormalities in heart failure patients
- Assess and follow patients with heart failure using devices for remote monitoring
- Manage patients with pulmonary hypertension
- Define indications for atrial fibrillation ablation in patients with heart failure
- Provide effective therapy for stroke prevention in atrial fibrillation using drugs and devices
- Recognize new innovations in electrophysiological devices for patients with heart failure
- Select appropriate patients with severe heart failure due to ischemic cardiomyopathy for percutaneous and surgical revascularization
- Define indications for percutaneous mitral valve repair
Heart failure (HF) is common, but often unrecognized and misdiagnosed. It affects over 6 million Americans and is one of few cardiovascular disorders on the rise. An estimated 670,000 new cases are diagnosed each year and this condition is a major cause of morbidity and mortality (80% of men and 70% of women less than 65 years of age who have HF will die within 8 years) and is the leading cause of hospitalizations of the elderly in the U.S. The importance of prevention through early identification and better treatment of risk factors such as hypertension, diabetes mellitus, obesity and lipid disorders and of education of both patients and physicians has been emphasized (Circulation 2011; 123:327, Up-to-date Nov. 2, 2015).
There is strong evidence that increased use of evidence based, life sustaining therapies and performance measures have a significant impact on the outcome of patients with HF (OPTIMIZE HF, JAMA 2007; 297:61). Recent data continues to show that life-saving drug and devices are underutilized (Eur Heart J 2009; 30:2493, Circulation 2010; 122:585, JACC 2016; 67:1062) indicating the need for education and incorporation of recent guidelines by clinicians (Circulation 2017;136: e137).
The development of biomarkers and imaging modalities has provided clinicians with important tools for diagnosis and assessment of prognosis. There is however a great need for education regarding an effective use of these new diagnostic modalities (Nature Reviews Cardiology 2012; 9:347). HF is the leading cause of hospitalizations and management of hospitalized patients is complex and challenging (Crit Path Cardiol 2015; 14:12). Valvular heart disease is an important cause of HF and effective therapy has been underutilized (Ann Thorac Surg 2010; 90:1904).
Atrial fibrillation (AF) is common in patients with HF and is the leading cause of cardioembolic stroke. A number of new agents have been added to the therapeutic options for prevention of thromboembolic complications in patients with AF, yet in spite of their proven efficacy approximately half of eligible patients remain untreated (JACC 2016; 67:2444).
Pulmonary hypertension (PH) is a major cause of right ventricular failure and an increasing cause of death. Delayed diagnosis and underutilization of effective therapy lead to poor outcome (JACC 2015; 65:1971).
Recent data have shown that drugs and devices that have been proven beneficial and are recommended in recent practice guidelines, are underutilized (JACC 2016; 67:1062), at the same time non-evidence-based implantation of expensive devices has been shown to be common (Sana M, et al JAMA 2011; 305:43). New guidelines regarding indications for resynchronization therapy are confusing and require clarifications (Miller R the heart.org June 18, 2012). Recent introduction of cardiac assist devices provides opportunity for improvement of quality of life and prolonged survival in patients with advanced HF, inappropriate and delayed referral for this procedure often results in poor outcomes (Slaughter MS, et al Curr Opin Cardiol 2011; 26:232). Recent information also suggests a significant individual variability in conformity to quality-of-care indicators and clinical outcome of patients with HF and a substantial gap in overall performance. In addition, according to a study analyzing the quality of health care in the U.S. on average, patients with HF received the recommended quality of care only 64% of the time (heart failure performance measurement set by the ACC/AHA 2010).
Establishing educational initiatives such as this program should help to reduce practice variability, eliminate gaps between guidelines and practice and improve the outcome of patients with HF (J Clin Med Res 2014; 6:173)
This program has been designed to provide cardiologists, internists, primary care physicians, pharmacists, nurses and other healthcare providers with the necessary information to increase knowledge with the goal of improving the care of patients with HF.
It is our policy to ensure balance, independence, objectivity and scientific
rigor. All persons involved in the selection, development and presentation
of content are required to disclose any real or apparent conflicts of
interest. All conflicts of interest will be resolved prior to an educational
activity being delivered to learners through one of the following mechanisms
1) altering the financial relationship with the commercial interest, 2)
altering the individual’s control over CME content about the products
or services of the commercial interest, and/or 3) validating the activity
content through independent peer review. All persons are also required
to disclose any discussions of off label/unapproved uses of drugs or devices.
Persons who refuse or fail to disclose are disqualified from participating
in the CME activity. Participants will be asked to evaluate whether the
speaker’s outside interests reflect a possible bias in the planning
or presentation of the activity. This information is used to plan future